Wells Fargo & Company MN Grows Stake in Janux Therapeutics, Inc. (NASDAQ:JANX)

Wells Fargo & Company MN boosted its position in shares of Janux Therapeutics, Inc. (NASDAQ:JANX) by 52.9% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 13,251 shares of the company’s stock after purchasing an additional 4,585 shares during the quarter. Wells Fargo & Company MN’s holdings in Janux Therapeutics were worth $709,000 at the end of the most recent reporting period.

Other large investors also recently bought and sold shares of the company. Rhumbline Advisers raised its position in Janux Therapeutics by 1.6% during the fourth quarter. Rhumbline Advisers now owns 38,153 shares of the company’s stock worth $2,043,000 after acquiring an additional 599 shares during the last quarter. China Universal Asset Management Co. Ltd. raised its position in shares of Janux Therapeutics by 10.9% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 11,128 shares of the company’s stock worth $596,000 after purchasing an additional 1,095 shares during the last quarter. Virtu Financial LLC lifted its stake in Janux Therapeutics by 17.5% in the 4th quarter. Virtu Financial LLC now owns 8,769 shares of the company’s stock valued at $469,000 after buying an additional 1,306 shares in the last quarter. Avanza Fonder AB acquired a new stake in Janux Therapeutics during the 4th quarter valued at $139,000. Finally, Meeder Asset Management Inc. purchased a new position in Janux Therapeutics during the fourth quarter worth $159,000. Institutional investors and hedge funds own 75.39% of the company’s stock.

Analysts Set New Price Targets

A number of research firms recently commented on JANX. HC Wainwright reaffirmed a “buy” rating and set a $70.00 price objective on shares of Janux Therapeutics in a research note on Monday, March 3rd. William Blair reaffirmed an “outperform” rating on shares of Janux Therapeutics in a research note on Friday, January 10th. Wedbush reissued an “outperform” rating and issued a $76.00 price objective (up previously from $75.00) on shares of Janux Therapeutics in a research report on Friday, February 28th. Finally, Scotiabank reduced their price objective on shares of Janux Therapeutics from $62.00 to $41.00 and set a “sector perform” rating on the stock in a research note on Friday, February 28th. One analyst has rated the stock with a hold rating, eight have issued a buy rating and two have issued a strong buy rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and a consensus target price of $95.25.

Janux Therapeutics Stock Performance

Janux Therapeutics stock opened at $32.05 on Friday. Janux Therapeutics, Inc. has a 1 year low of $22.52 and a 1 year high of $71.71. The firm has a 50 day moving average price of $29.80 and a 200 day moving average price of $42.70. The company has a market cap of $1.90 billion, a price-to-earnings ratio of -27.39 and a beta of 3.27.

Janux Therapeutics (NASDAQ:JANX) last announced its quarterly earnings data on Thursday, February 27th. The company reported ($0.36) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.49) by $0.13. Janux Therapeutics had a negative net margin of 463.91% and a negative return on equity of 10.47%. Sell-side analysts predict that Janux Therapeutics, Inc. will post -1.38 EPS for the current year.

Insider Buying and Selling at Janux Therapeutics

In other news, insider Andrew Hollman Meyer sold 3,334 shares of the business’s stock in a transaction on Monday, April 21st. The shares were sold at an average price of $30.00, for a total transaction of $100,020.00. Following the transaction, the insider now directly owns 82,139 shares of the company’s stock, valued at approximately $2,464,170. The trade was a 3.90 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director Ra Capital Management, L.P. acquired 341,742 shares of the firm’s stock in a transaction on Wednesday, March 5th. The stock was purchased at an average cost of $30.64 per share, with a total value of $10,470,974.88. Following the completion of the transaction, the director now owns 9,658,988 shares in the company, valued at $295,951,392.32. The trade was a 3.67 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Over the last 90 days, insiders sold 10,002 shares of company stock valued at $348,203. Company insiders own 29.40% of the company’s stock.

Janux Therapeutics Company Profile

Janux Therapeutics, Inc, a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.